Sobi appoints former Biogen exec as head of technical operations

22 August 2018

Rare diseases specialist Swedish Orphan Biovitrum (STO: SOBI) has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations.

Ms de Jonge Schuermans will join on October 1, 2018, and be part of Sobi’s Executive Committee. She joins Sobi from Biogen (Nasdaq: BIIB) where she served as vice president for global supply chain operations and strategic partnerships and as an executive board member of Biogen International GmbH.

Ms de Jonge Schuermans brings more than 15 years of experience in the healthcare industry from Biogen, Stryker and Novartis. She has a track record of putting processes and systems in place, and of driving transformation in cross-functional and cross-cultural settings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK